Ohio department of health bans hydroxychloroquine—then governor steps in to halt ban

The ODH announced on Wednesday that a ruling was issued by the Ohio Board of Pharmacy prohibiting the dispensing or selling of both hydroxychloroquine.

ADVERTISEMENT
Image
Sam Edwards High Level Alberta
ADVERTISEMENT

The Ohio Department of Health (ODH) announced on Wednesday that a ruling was issued by the Ohio Board of Pharmacy prohibiting the dispensing or selling of both hydroxychloroquine and chloroquine as coronavirus treatments, according to The Daily Wire.

Ohio GOP Gov. Mike DeWine, however, stepped in on Thursday and publicly asked the State Medical Board and the Ohio Board of Pharmacy to “halt the new rule issued Thursday that bans the use of hydroxychloroquine as a treatment of COVID-19.”

“I agree with the statement from Dr. Steven Hahn, Commissioner of the Food and Drug Administration, that the decision about prescribing hydroxychloroquine to treat COVID-19 should be between a doctor and a patient,” tweeted DeWine.

“The Board of Pharmacy and the State Medical Board of Ohio should revisit the issue, listen to the best medical science, and open the process up for comment and testimony from experts. Therefore, I am asking the @OhioRxBoard to halt their new rule prohibiting the selling or dispensing of hydroxychloroquine or chloroquine for the treatment or prevention of COVID-19.”

Melanie Amato, an ODH spokeswoman noted that hydroxychloroquine is not effective in treating coronavirus, when speaking to the press on Thursday.

A statement was issued by the Ohio Department of Health regarding the Board of Pharmacy rule.

The statement reads:

On July 30, 2020, Board of Pharmacy rule 4729:5-5-21 of the Administrative Code goes into effect. In general, the rule prohibits all terminal distributors (including pharmacist, prescriber clinics, out-of-state pharmacies, and institutional facilities) from selling or dispensing hydroxychloroquine and chloroquine for the treatment or prevention of COVID-19.

Please be advised that this rule replaces emergency rule 4729-5-30.2 and that all approvals for the use of these medications made under that rule are no longer applicable.

The implementation of the rule is based on the following developments:

June 15, 2020: Based on ongoing analysis and emerging scientific data, FDA has revoked the emergency use authorization to use hydroxychloroquine and chloroquine to treat COVID-19 in certain hospitalized patients when a clinical trial is unavailable or participation is not feasible. The agency made this determination based on recent results from a large, randomized clinical trial in hospitalized patients that found these medicines showed no benefit for decreasing the likelihood of death or speeding recovery. This outcome was consistent with other new data, including those showing the suggested dosing for these medicines are unlikely to kill or inhibit the virus that causes COVID-19. As a result, FDA determined that the legal criteria for the EUA are no longer met.

July 1, 2020: A summary of the FDA review of safety issues with the use of hydroxychloroquine and chloroquine to treat hospitalized patients with COVID-19 is now available. This includes reports of serious heart rhythm problems and other safety issues, including blood and lymph system disorders, kidney injuries, and liver problems and failure.

DeWine also announced earlier this week that child care providers can go back to pre-pandemic class sizes and ratios beginning Aug. 9. He added that providers that choose to remain at the lower ratios will be subsidized.

ADVERTISEMENT
ADVERTISEMENT

Join and support independent free thinkers!

We’re independent and can’t be cancelled. The establishment media is increasingly dedicated to divisive cancel culture, corporate wokeism, and political correctness, all while covering up corruption from the corridors of power. The need for fact-based journalism and thoughtful analysis has never been greater. When you support The Post Millennial, you support freedom of the press at a time when it's under direct attack. Join the ranks of independent, free thinkers by supporting us today for as little as $1.

Support The Post Millennial

Remind me next month

To find out what personal data we collect and how we use it, please visit our Privacy Policy

ADVERTISEMENT
ADVERTISEMENT
By signing up you agree to our Terms of Use and Privacy Policy
ADVERTISEMENT
© 2024 The Post Millennial, Privacy Policy | Do Not Sell My Personal Information